Literature DB >> 4084429

Antagonism of the muscarinic effects of edrophonium with atropine or glycopyrrolate. A comparative study.

R K Mirakhur.   

Abstract

The efficacy of atropine or glycopyrrolate in doses of 10 or 20 micrograms kg-1 and 5 or 10 micrograms kg-1, respectively, has been compared when administered to block the muscarinic effects of edrophonium 0.5 mg kg-1 administered for the reversal of neuromuscular blockade. Both doses of atropine and the higher dose of glycopyrrolate prevented any edrophonium-induced decreases in heart rate; glycopyrrolate at this dose was associated with tachycardia. Atropine and edrophonium could be safely administered together in a mixture. The control of oropharyngeal secretions was adequate even with the lower doses of both anticholinergic agents. Atropine 10 micrograms kg-1 appears to be a better anticholinergic agent for use with edrophonium.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4084429     DOI: 10.1093/bja/57.12.1213

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  5 in total

Review 1.  A simulation of neuromuscular function and heart rate during induction, maintenance, and reversal of neuromuscular blockade.

Authors:  R R Jaklitsch; D R Westenskow
Journal:  J Clin Monit       Date:  1990-01

Review 2.  Anticholinergic drugs and anaesthesia.

Authors:  R K Mirakhur
Journal:  Can J Anaesth       Date:  1988-09       Impact factor: 5.063

Review 3.  Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults.

Authors:  Ana-Marija Hristovska; Patricia Duch; Mikkel Allingstrup; Arash Afshari
Journal:  Cochrane Database Syst Rev       Date:  2017-08-14

4.  Edrophonium and plasma cholinesterase activity.

Authors:  R K Mirakhur
Journal:  Can Anaesth Soc J       Date:  1986-09

Review 5.  New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use.

Authors:  C S Reilly; W S Nimmo
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.